Qube Research & Technologies Ltd acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 23,522 shares of the medical research company's stock, valued at approximately $957,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Natera by 7.5% during the fourth quarter. JPMorgan Chase & Co. now owns 5,079,091 shares of the medical research company's stock worth $474,337,000 after buying an additional 355,574 shares during the period. State Street Corp lifted its stake in shares of Natera by 12.6% during the fourth quarter. State Street Corp now owns 1,829,822 shares of the medical research company's stock worth $170,887,000 after buying an additional 204,621 shares during the period. Marshall Wace LLP lifted its stake in shares of Natera by 33.5% during the fourth quarter. Marshall Wace LLP now owns 1,815,919 shares of the medical research company's stock worth $169,589,000 after buying an additional 456,158 shares during the period. American Century Companies Inc. lifted its position in Natera by 6.8% during the fourth quarter. American Century Companies Inc. now owns 1,284,116 shares of the medical research company's stock valued at $119,924,000 after purchasing an additional 81,658 shares during the period. Finally, Geode Capital Management LLC lifted its position in Natera by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 1,127,087 shares of the medical research company's stock valued at $105,258,000 after purchasing an additional 36,243 shares during the period. 96.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Cowen decreased their target price on shares of Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Piper Sandler boosted their target price on shares of Natera from $60.00 to $70.00 in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $80.00 to $100.00 in a report on Friday, August 5th. BTIG Research lifted their price objective on shares of Natera to $95.00 in a report on Monday. Finally, Cowen cut their price objective on shares of Natera from $110.00 to $100.00 in a report on Friday, May 6th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $93.64.

Natera Stock Down 4.6 %

Natera (NASDAQ:NTRA – Get Rating) last released its earnings results on Thursday, August 4th. The medical research company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.03). The company had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. Natera had a negative return on equity of 95.97% and a negative net margin of 79.57%. The firm's revenue for the quarter was up 39.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.32) EPS. Equities analysts forecast that Natera, Inc. will post -5.73 earnings per share for the current fiscal year.

Insider Activity at Natera

In other Natera news, COO Robert Alan Schueren sold 572 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $46.26, for a total value of $26,460.72. Following the transaction, the chief operating officer now directly owns 572 shares of the company's stock, valued at approximately $26,460.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Robert Alan Schueren sold 572 shares of Natera stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $46.26, for a total transaction of $26,460.72. Following the transaction, the chief operating officer now owns 572 shares in the company, valued at $26,460.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 1,652 shares of the firm's stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $59,075.52. Following the sale, the chief executive officer now directly owns 64,777 shares of the company's stock, valued at approximately $2,316,425.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,966 shares of company stock valued at $550,755. Corporate insiders own 10.27% of the company's stock.

Natera Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Stories

• Get a free copy of the StockNews.com research report on Natera (NTRA)
• Which Semiconductor Stocks Are Ready For Big Price Moves?
• Miners Advance On Earnings Despite Broader Economic Challenges
• Lowe's Stands Out Amid Q2 Retail Reports
• Agilent Technologies Proves Its Worth VS Illumina
• Target's Results Cap Upside Potential For Retail Stocks

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.